AVITA MED LTD/S ADR (NASDAQ:RCEL) shares traded up 7.7% during mid-day trading on Friday . The stock traded as high as $8.47 and last traded at $8.24, 571,682 shares were traded during trading. An increase of 98% from the average session volume of 288,106 shares. The stock had previously closed at $7.65.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded AVITA MED LTD/S from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Friday, November 29th. ValuEngine lowered AVITA MED LTD/S from a “hold” rating to a “sell” rating in a research report on Friday, November 1st. Finally, Lake Street Capital lifted their price objective on AVITA MED LTD/S from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st.
The firm has a market cap of $617.18 million, a PE ratio of -21.10 and a beta of 1.32. The company has a 50-day moving average of $8.47.
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.
Featured Story: Equal Weight Rating
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.